SG11202111221YA - Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) - Google Patents
Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1)Info
- Publication number
- SG11202111221YA SG11202111221YA SG11202111221YA SG11202111221YA SG11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA
- Authority
- SG
- Singapore
- Prior art keywords
- p27kip1
- small molecules
- kinase inhibitor
- dependent kinase
- bind cyclin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817924P | 2019-03-13 | 2019-03-13 | |
| PCT/US2020/022475 WO2020186110A1 (en) | 2019-03-13 | 2020-03-12 | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111221YA true SG11202111221YA (en) | 2021-11-29 |
Family
ID=72427117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111221YA SG11202111221YA (en) | 2019-03-13 | 2020-03-12 | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220177457A1 (zh) |
| EP (1) | EP3937926A4 (zh) |
| KR (1) | KR20210150411A (zh) |
| CN (1) | CN113825506A (zh) |
| AU (1) | AU2020235112A1 (zh) |
| CA (1) | CA3136242A1 (zh) |
| SG (1) | SG11202111221YA (zh) |
| WO (1) | WO2020186110A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336735B (zh) * | 2021-06-08 | 2022-09-30 | 常州大学 | 一种尿石素类化合物、制备方法、药物组合物及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2643579C (en) * | 2006-02-28 | 2018-05-15 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| WO2007127263A2 (en) * | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Therapeutic uses of urolithins |
| MX2010010431A (es) * | 2008-03-25 | 2010-11-25 | Paloma Pharmaceuticals Inc | Metodos para tratar desordenes fibroticos. |
| JP5944823B2 (ja) * | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| CA2972013C (en) * | 2013-12-23 | 2020-04-28 | Amazentis Sa | Process-scale synthesis of urolithins |
-
2020
- 2020-03-12 AU AU2020235112A patent/AU2020235112A1/en not_active Abandoned
- 2020-03-12 SG SG11202111221YA patent/SG11202111221YA/en unknown
- 2020-03-12 CN CN202080033970.5A patent/CN113825506A/zh active Pending
- 2020-03-12 US US17/438,857 patent/US20220177457A1/en active Pending
- 2020-03-12 KR KR1020217032892A patent/KR20210150411A/ko unknown
- 2020-03-12 WO PCT/US2020/022475 patent/WO2020186110A1/en unknown
- 2020-03-12 EP EP20769404.3A patent/EP3937926A4/en not_active Withdrawn
- 2020-03-12 CA CA3136242A patent/CA3136242A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210150411A (ko) | 2021-12-10 |
| WO2020186110A1 (en) | 2020-09-17 |
| EP3937926A4 (en) | 2022-12-14 |
| CN113825506A (zh) | 2021-12-21 |
| AU2020235112A1 (en) | 2021-11-04 |
| CA3136242A1 (en) | 2020-09-17 |
| EP3937926A1 (en) | 2022-01-19 |
| US20220177457A1 (en) | 2022-06-09 |
| AU2020235112A8 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282928A (en) | Data protocols related to vaporization | |
| CA188880S (en) | Bookshelf | |
| EP3902805A4 (en) | CYCLIN DEPENDENT KINASE INHIBITORS | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| IL283849A (en) | Proof of work for blockchain applications | |
| HUE050842T2 (hu) | Janus-kináz inhibitor | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL275207A (en) | An oxyfluoropiperidine derivative as a kinase inhibitor | |
| EP3804707A4 (en) | KINASE INHIBITORS | |
| EP3613737A4 (en) | NEW INHIBITOR OF THE CYCLINE-DEPENDENT KINASE CDK9 | |
| GB201819126D0 (en) | Inhibitor compounds | |
| GB201811403D0 (en) | Antibody molecules | |
| EP3415524A4 (en) | INHIBITOR OF EXPRESSION OF α-SYNUCLEIN | |
| EP3641776C0 (en) | ATROPISOMERISM FOR IMPROVED SELECTIVITY OF KINASE INHIBITORS | |
| ZA202102261B (en) | Spak kinase inhibitors as neuroprotective agents | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| EP3902801A4 (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| IL292799A (en) | Antibodies against siglec-9 | |
| SG11202111221YA (en) | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| ZAF201801269S (en) | Chassis | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201805450D0 (en) | Movable chassis | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds |